Search Result

Results for "

dominant

" in MedChemExpress (MCE) Product Catalog:

By Targets:	Antibiotic (1) Bacterial (1) Biochemical Assay Reagents (2) Calmodulin (1) CaMK (1) CaSR (1) CCR (1) CDK (4) CFTR (1) Cytochrome P450 (2) Drug Metabolite (2) Fungal (1) Gap Junction Protein (1) Glucosylceramide Synthase (GCS) (4) GSK-3 (1) HDAC (1) HIV (1) HSP (2) Huntingtin (1) Integrin (1) Interleukin Related (1) MEK (1) MicroRNA (2) Molecular Glues (1) Notch (1) P-glycoprotein (2) Parasite (1) PKA (1) PKC (2) PPAR (2) Raf (1) Reference Standards (1) SOD (1) Thyroid Hormone Receptor (1) Vasopressin Receptor (2)
By Research Areas:	Cancer (5) Cardiovascular Disease (1) Endocrinology (3) Infection (1) Inflammation/Immunology (3) Metabolic Disease (17) Neurological Disease (3)
Oligonucleotides:	Antisense Oligonucleotides (2)

Inhibitors & Agonists

Screening Libraries

Biochemical Assay Reagents

Peptides

Natural
Products

Recombinant Proteins

Antibodies

Oligonucleotides

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-22167

Methyl 2-hydroxy-4-methylvalerate	Biochemical Assay Reagents	Others
Methyl 2-hydroxy-4-methylvalerate is one of dominant volatile compounds in Zhenjiang aromatic vinegar. Methyl 2-hydroxy-4-methylvalerate is used for charting flavour biosynthesis networks of vinegar microbiota .

HY-145694

CDK5-IN-3	CDK	Metabolic Disease
CDK5-IN-3 (compound 11) is a potent and selective CDK5 inhibitor, with IC₅₀s of 0.6 nM and 18 nM for CDK5/p25 and CDK2/CycA, respectively. CDK5-IN-3 can be used for the research of autosomal dominant polycystic kidney disease (ADPKD) .

HY-P2203

SAHM1 1 Publications Verification	Notch	Inflammation/Immunology
SAHM1, a peptide mimetic of a dominant negative form of mastermind-like (MAML), inhibits canonical Notch transcription complex formation. SAHM1 can be used for the research of allergic airway inflammation in mice .

HY-139290A

RGLS4326 sodium RG4326 sodium	MicroRNA	Cancer
RGLS4326 sodium is a first-in-class, short oligonucleotide inhibitor of microRNA-17 (miR-17). RGLS4326 sodium can be used for the research of autosomal dominant polycystic kidney disease (ADPKD). RGLS4326 sodium inhibits miR-17 function in HeLa cells with an EC₅₀ value of 28.3 nM .

HY-139290

RGLS4326 RG4326	MicroRNA	Metabolic Disease Cancer
RGLS4326 (RG4326) is a first-in-class, short oligonucleotide inhibitor of microRNA-17 (miR-17). RGLS4326 can be used for the research of autosomal dominant polycystic kidney disease (ADPKD). RGLS4326 inhibits miR-17 function in HeLa cells with an EC₅₀ value of 28.3 nM .

HY-146272

Vasopressin V2 receptor antagonist 1	Vasopressin Receptor	Metabolic Disease
Vasopressin V2 receptor antagonist 1 (Compound 4g) is a vasopressin V₂ receptor (V₂R) antagonist with a K_i of 3.8 nM. Vasopressin V2 receptor antagonist 1 can be used for autosomal dominant polycystic kidney disease (ADPKD) research .

HY-22167R

Methyl 2-hydroxy-4-methylvalerate (Standard)	Reference Standards Biochemical Assay Reagents	Others
Methyl 2-hydroxy-4-methylvalerate (Standard) is the analytical standard of Methyl 2-hydroxy-4-methylvalerate. This product is intended for research and analytical applications. Methyl 2-hydroxy-4-methylvalerate is one of dominant volatile compounds in Zhenjiang aromatic vinegar. Methyl 2-hydroxy-4-methylvalerate is used for charting flavour biosynthesis networks of vinegar microbiota[1].

HY-151878

CDK7-IN-20	CDK GSK-3	Metabolic Disease
CDK7-IN-20 is a potent, selective and irreversible CDK7 (CDK) inhibitor with an IC₅₀ value of 4 nM. CDK7-IN-20 displays >206-fold selectivity for CDK7 over CDK1, CDK2, CDK3, CDK5, CDK6, CDK9 and CDK12 . CDK7-IN-20 has the potential for autosomal dominant polycystic kidney disease (ADPKD) research .

HY-W702908

DM-4107	P-glycoprotein	Metabolic Disease
DM-4107 is a major metabolite of Tolvaptan (HY-17000) that is metabolized primarily by the CYP3A4 enzyme in the liver. DM-4107 inhibits the ability of human liver transporters NTCP, BSEP, MRP3, MRP4 (IC₅₀ values are 95.6, 119, 61.2, 37.9 μM, respectively) and bile acid transport in SCHH cells. DM-4107 can be used in the study of autosomal dominant polycystic kidney disease (ADPKD) .

HY-161524

HDAC6-IN-43	HDAC	Cancer
HDAC6-IN-43 (compound 26) is a potent HDAC inhibitor. HDAC6-IN-43 effectively inhibits several HDACs, notably HDAC1, HDAC2, and HDAC6 (IC₅₀ < 150 nM), displaying a particularly high sensitivity towards HDAC6 (IC₅₀ = 11 nM). HDAC6-IN-43 can be used for the research of autosomal dominant polycystic kidney disease (ADPKD) .

HY-149770

CYP4A11/CYP4F2-IN-2	Cytochrome P450	Metabolic Disease
CYP4A11/CYP4F2-IN-2 (compound 15) is an orally available inhibitor of CYP4A11/4F2 with IC₅₀s of 120 nM and 220 nM, respectively. CYP4A11/CYP4F2-IN-2 inhibits 20-HETE production in rat kidney and has potential inhibitory effects on diabetic nephropathy and autosomal dominant polycystic kidney disease .

HY-W702907

DM-4103	P-glycoprotein	Metabolic Disease
DM-4103 is a major metabolite of Tolvaptan (HY-17000) that is metabolized primarily by the CYP3A4 enzyme in the liver. DM-4103 inhibits the ability of human liver transporters NTCP, BSEP, MRP2, MRP3, MRP4 (IC₅₀ values are 16.3, 4.15, 51.0, 44.6, 4.26 μM, respectively) and bile acid transport in SCHH cells. DM-4103 can be used in the study of autosomal dominant polycystic kidney disease (ADPKD) .

HY-N10348

Progoitrin	Others	Endocrinology
Progoitrin is the dominant glucosinolate in incriminated crops. Antithyroid activity .

HY-N8731

Lutein dipalmitate Helenien	Others	Metabolic Disease
Lutein dipalmitate (Helenien), a Lutein ester, is a dominant compound in Lutein supplement .

HY-P2473

Neurogranin (48-76), human	Calmodulin PKC CaMK PKA	Neurological Disease
Neurogranin (48-76), human is a dominant endogenous peptide in Alzheimer's disease (AD) brain tissue. Neurogranin (48-76) is a potential biomarker for synaptic function in AD .

HY-153911

H2-Gamendazole	HSP CFTR	Endocrinology
H2-Gamendazole is a derivative of Lonidamine that reduces cyst formation in polycystic kidney disease and is used in autosomal dominant polycystic kidney disease research .

HY-W098348

N-Methyltaurine	Parasite	Metabolic Disease
N-Methyltaurine is a taurine-derived metabolite with a minimum effective concentration of 10 μM for maintaining hamster sperm motility. N-Methyltaurine is the dominant osmolyte of Vespermum virulentum .

HY-U00036A

Naveglitazar LY519818	PPAR	Metabolic Disease
Naveglitazar (LY519818) is a nonthiozolidinedione peroxisome proliferator-activated receptor (PPAR) α-γ dual, γ-dominant agonist that has shown glucose-lowering potential in animal models .

HY-106844A

(+)-EMD 57033	Others	Cardiovascular Disease
(+)-EMD 57033 is a cardiac troponin C (cTnC) activator, is a dominant Ca ²⁺ sensitizer. (+)-EMD 57033 binds the cardiac/slow skeletal troponin C isoform and exerts myocardial contractile promotion function .

HY-U00036

Naveglitazar racemate LY519818 racemate	PPAR	Metabolic Disease
Naveglitazar racemate (LY519818 racemate) is the racemate of Naveglitazar. Naveglitazar is a nonthiozolidinedione peroxisome proliferator-activated receptor (PPAR) α-γ dual, γ-dominant agonist that has shown glucose-lowering potential in animal models .

HY-P3838

Protein Kinase C (gamma) Peptide	PKC	Others
Protein Kinase C γ Peptide is a peptide fragment of Protein Kinase Cγ. Protein Kinase Cγ is a protein causative for dominant ataxia, that can negatively regulate nuclear import of recessive-ataxia-related aprataxin .

HY-150245

mHTT-IN-1	Huntingtin	Neurological Disease
mHTT-IN-1 (Example 1) is a potent mutant huntingtin (mHTT) inhibitor. mHTT is toxic and a major cause of the inherited autosomal dominant neurodegenerative disorder, Huntington's disease (HD). mHTT-IN-1 conducts the reduction of mHTT with an EC₅₀ value of 46 nM .

HY-16743C

Ibiglustat hydrochloride Venglustat hydrochloride; SAR402671 hydrochloride; GZ402671 hydrochloride	Glucosylceramide Synthase (GCS)	Metabolic Disease
Ibiglustat hydrochloride is an orally active, brain-penetrant glucosylceramide synthase (GCS) inhibitor. Ibiglustat hydrochloride can be used for the research of Gaucher disease type 3, Parkinson's disease associated with GBA mutations, Fabry disease, GM2 gangliosidosis, and autosomal dominant polycystic kidney disease .

HY-14401

Encaleret CLTX-305; JTT-305; MK-5442	CaSR Thyroid Hormone Receptor	Endocrinology
Encaleret (CLTX-305) is an orally active antagonist of the calcium-sensing receptor (CaSR), with an IC₅₀ of 0.012 μM. Encaleret can promote the secretion of parathyroid hormone. Encaleret can be used in the research of diseases such as osteoporosis and autosomal dominant hypocalcemia type 1 .

HY-16743

Ibiglustat 3 Publications Verification Venglustat; SAR402671; GZ402671	Glucosylceramide Synthase (GCS)	Metabolic Disease
Ibiglustat (Venglustat) is an orally active, brain-penetrant glucosylceramide synthase (GCS) inhibitor. Ibiglustat can be used for the research of Gaucher disease type 3, Parkinson's disease associated with GBA mutations, Fabry disease, GM2 gangliosidosis, and autosomal dominant polycystic kidney disease .

HY-121432

Kitol	Drug Metabolite	Others
Kitol is peptide used for after-sun repair cosmetics. The dominant degradation reaction for vitamin A derivatives is heat-induced formation of kitols, i.e., dimers or higher oligomers. Vitamin A esters are used as a model system to evaluate microcalorimetry as a tool for monitoring the stability of heat-sensitive substances .

HY-NP026

Spirulina C-phycocyanin C-phycocyaninfromporphyratenera	SOD Integrin	Inflammation/Immunology
Spirulina C-phycocyanin, a component of the light-harvesting phycobilisome complex in photosystem II, is a highly dominant chromoprotein in Spirulina. Spirulina C-phycocyanin can be detected by Raman spectral measurement. Spirulina C-phycocyanin has antioxidant, anti-inflammatory, antiplatelet, liver-protective and cholesterol-lowering effects .

HY-16743B

Ibiglustat succinate 3 Publications Verification Venglustat succinate; SAR402671 succinate; GZ402671 succinate	Glucosylceramide Synthase (GCS)	Neurological Disease
Ibiglustat (Venglustat) succinate is an orally active, brain-penetrant glucosylceramide synthase (GCS) inhibitor. Ibiglustat succinate can be used for the research of Gaucher disease type 3, Parkinson's disease associated with GBA mutations, Fabry disease, GM2 gangliosidosis, and autosomal dominant polycystic kidney disease .

HY-162394

Vasopressin V2 receptor antagonist 2	Vasopressin Receptor	Metabolic Disease
Vasopressin V2 receptor antagonist 2 (Compound 33) is an antagonist of the arginine vasopressin V₂ receptor (V₂R) with a K_i value of 6.2 nM. Vasopressin V2 receptor antagonist 2 can effectively reduce cAMP levels, thereby inhibiting the growth of renal cysts[1].

HY-16743A

Ibiglustat (L-Malic acid) 3 Publications Verification Venglustat (L-Malic acid); SAR402671 (L-Malic acid); GZ402671 (L-Malic acid)	Glucosylceramide Synthase (GCS)	Metabolic Disease
Ibiglustat (Venglustat) L-Malic acid is an orally active, brain-penetrant glucosylceramide synthase (GCS) inhibitor. Ibiglustat L-Malic acid can be used for the research of Gaucher disease type 3, Parkinson's disease associated with GBA mutations, Fabry disease, GM2 gangliosidosis, and autosomal dominant polycystic kidney disease .

HY-145693

CDK5-IN-2	CDK	Others
CDK5-IN-2 (compound 15) is a highly selective CDK5 inhibitor with IC₅₀s of 0.2 and 23 for CDK5/p25 and CDK2/CycA, respectively .

HY-129065

Nourseothricin sulfate 1 Publications Verification Streptothricin sulfate	Fungal Bacterial Antibiotic	Infection
Nourseothricin sulfate (Streptothricin sulfate) is a broad-spectrum antibiotic that destroys the outer membrane of Gram-negative bacteria and is a dominant selective marker for *Fonsecaea pedrosoi* . Nourseothricin sulfate inhibits protein biosynthesis in prokaryotic cells and strongly inhibits the growth of eukaryotes like fungi and can also be used as a elective marker for a wide range of organisms including bacteria, yeast, filamentous fungi, and plant cells .

HY-P5389

Connexin mimetic peptide 40GAP27	Gap Junction Protein	Others
Connexin mimetic peptide 40GAP27 is a biological active peptide. (This peptide corresponds to the GAP27 domain of the second extracellular loop of dominant vascular connexin (Cx40), designated as 40Gap 27. It was used to investigate mechanisms through which oxidant stress impairs communication via gap junctions. When administered, 40Gap27attenuates endothelium-dependent subintimal smooth muscle hyperpolarization.)

HY-176255

TBK1 degrader-4	Molecular Glues Interleukin Related CCR	Inflammation/Immunology
TBK1 degrader-4 (Compound 30) is a molecular glue degrader targeting TBK1. TBK1 degrader-4 effectively inhibits cyst growth, alleviates inflammation, and reduces the levels of pro-inflammatory factors such as Ccl2, IFNβ, and IL-6. TBK1 degrader-4 is promising for research of autosomal dominant polycystic kidney disease (ADPKD) .

HY-117051

STA-2842	HSP	Cancer
STA-2842 is an inhibitor of heat shock protein HSP90 with potential to inhibit autosomal dominant polycystic kidney disease (ADPKD). ADPKD is caused by inherited mutations in the PKD1 or PKD2 genes that abnormally activate multiple signaling proteins and pathways that regulate cell proliferation. STA-2842 can significantly reduce initial renal cyst formation and kidney growth in mice, and slow disease progression in mice with existing cysts.

HY-P5503

Pol (476-484), HIV-1 RT Epitope	HIV	Others
Pol (476-484), HIV-1 RT Epitope is a biological active peptide. (This is a reverse transcriptase (RT) epitope (Pol residues 476-484). Within HIV-1 RT the peptide appears to be the dominant HLA A*0201-restricted epitope. Was used to investigate possible mechanisms behind HIV-1 escape from CTL. IV9 is the actual epitope processed and presented in HIV-1-infected cell lines.)

HY-144117

GFB-12811	CDK	Metabolic Disease
GFB-12811 is a high selective CDK5 inhibitor with an IC₅₀ of 2.3 nM .

HY-121057

3-Hydroxyflunitrazepam 3-OH FNTZ	Drug Metabolite Cytochrome P450	Metabolic Disease
3-Hydroxyflunitrazepam (3-OH FNTZ) is the major metabolite of Flunitrazepam (FNTZ), generated via 3-hydroxylation by CYP3A4 (K_m = 286 μM), and represents the dominant metabolic pathway (>80%) in liver microsomes. Its formation is significantly inhibited by CYP3A4 inhibitors such as Ketoconazole (HY-B0105) (IC₅₀ = 0.11 μM) and Ritonavir (HY-90001) (IC₅₀ = 0.041 μM), indicating a strong dependence on CYP3A4 activity and potential drug interactions .

HY-18652A

Avutometinib potassium Ro 5126766 potassium; CH5126766 potassium	Raf MEK	Cancer
Avutometinib (CH5126766) (potassium) is a RAF/MEK clamp that potently inhibits RAF/MEK kinase activity and induces dominant negative RAF-MEK complexes preventing phosphorylation of MEK by ARAF, BRAF and CRAF. Avutometinib (potassium) shows anti-proliferative potency across tumor cell lines carrying KRAS mutations including PDAC cell lines. Avutometinib (potassium) induces tumor inhibition and increases survival in a KRAS/p53 pancreatic cancer mouse model. Avutometinib (potassium) is promising for research of low-grade-serous-ovarian-carcinoma (LGSOC), ovarian cancer and pancreatic ductal adenocarcinoma (PDAC) .

HY-N12962

11S(12R)-EET	Others	Others
11S(12R)-EET is a dominant enantiomer of epoxytrienoic acid (EET) that is metabolized at a higher rate in rat organs. It shows enantiomeric-dependent reaction selectivity in hydration, especially in the case of 11,12-EET, where water addition is non-regioselective, while in 8,9-EET, water addition occurs mainly at the C9 position. In addition, 11S(12R)-EET generates diol products with specific stereochemistry through enzymatic hydration reactions, which are affected by the selective recognition of epoxidases, reaction conversion rates, and substrate binding parameters .

Cat. No.	Product Name

HY-L033

Peptidomimetic Library	372 compounds
Peptidomimetics are compounds whose essential elements (pharmacophore) mimic a natural peptide or protein in 3D space and which retain the ability to interact with the biological target and produce the same biological effect. Peptidomimetics are designed to circumvent some of the problems associated with a natural peptide: e.g. stability against proteolysis (duration of activity) and poor bioavailability. Certain other properties, such as receptor selectivity or potency, often can be substantially improved. The design and synthesis of peptidomimetics are most important because of the dominant position peptide and protein-protein interactions play in molecular recognition and signaling, especially in living systems. Hence mimics have great potential in drug discovery. MCE Peptidomimetic Library contains 372 compounds including peptoid, α-helix mimetics, β-turn/sheets mimetics, etc. This library is an indispensable tool of structure-activity relationships in drug discovery.

Peptidomimetic Library

372 compounds

Peptidomimetics are compounds whose essential elements (pharmacophore) mimic a natural peptide or protein in 3D space and which retain the ability to interact with the biological target and produce the same biological effect. Peptidomimetics are designed to circumvent some of the problems associated with a natural peptide: e.g. stability against proteolysis (duration of activity) and poor bioavailability. Certain other properties, such as receptor selectivity or potency, often can be substantially improved. The design and synthesis of peptidomimetics are most important because of the dominant position peptide and protein-protein interactions play in molecular recognition and signaling, especially in living systems. Hence mimics have great potential in drug discovery.

MCE Peptidomimetic Library contains 372 compounds including peptoid, α-helix mimetics, β-turn/sheets mimetics, etc. This library is an indispensable tool of structure-activity relationships in drug discovery.

HY-L173

Anti-Ovarian Cancer Compound Library	2,391 compounds
Ovarian cancer is the most common cause of death in female genital malignancies, with the highest mortality rate in female genital malignancies. It is characterized by difficulty in detection in the early stage of the disease, high recurrence rate and poor prognosis. In fact, ovarian cancer includes many pathologic types. It is usually divided into epithelial ovarian cancer, malignant germ cell tumors and sex cord stromal tumors, of which epithelial ovarian cancer is the most dominant form. Clinical treatment of ovarian cancer prioritizes surgery combined with paclitaxel chemotherapy. However, due to the spread and drug resistance of tumor cells, the recurrence of ovarian cancer is high. In this case, combined with traditional methods, the development of new therapeutic agents can help to improve the treatment effect of ovarian cancer. MCE designs a unique collection of 2,391 compounds with definite or potential anti-ovarian cancer activity, which mainly targeting the main targets of ovarian cancer such as PARP, ATM/ATR, VEGFR and HIF/HIF Prolyl-Hydroxylase, etc. It is an essential tool for development and research of anti-ovarian compounds.

Anti-Ovarian Cancer Compound Library

2,391 compounds

Ovarian cancer is the most common cause of death in female genital malignancies, with the highest mortality rate in female genital malignancies. It is characterized by difficulty in detection in the early stage of the disease, high recurrence rate and poor prognosis. In fact, ovarian cancer includes many pathologic types. It is usually divided into epithelial ovarian cancer, malignant germ cell tumors and sex cord stromal tumors, of which epithelial ovarian cancer is the most dominant form. Clinical treatment of ovarian cancer prioritizes surgery combined with paclitaxel chemotherapy. However, due to the spread and drug resistance of tumor cells, the recurrence of ovarian cancer is high. In this case, combined with traditional methods, the development of new therapeutic agents can help to improve the treatment effect of ovarian cancer.

MCE designs a unique collection of 2,391 compounds with definite or potential anti-ovarian cancer activity, which mainly targeting the main targets of ovarian cancer such as PARP, ATM/ATR, VEGFR and HIF/HIF Prolyl-Hydroxylase, etc. It is an essential tool for development and research of anti-ovarian compounds.

Cat. No.	Product Name	Type

HY-NP026

Spirulina C-phycocyanin C-phycocyaninfromporphyratenera	Native Proteins
Spirulina C-phycocyanin, a component of the light-harvesting phycobilisome complex in photosystem II, is a highly dominant chromoprotein in Spirulina. Spirulina C-phycocyanin can be detected by Raman spectral measurement. Spirulina C-phycocyanin has antioxidant, anti-inflammatory, antiplatelet, liver-protective and cholesterol-lowering effects .

Cat. No.	Product Name	Target	Research Area

HY-P2203

SAHM1 1 Publications Verification	Notch	Inflammation/Immunology
SAHM1, a peptide mimetic of a dominant negative form of mastermind-like (MAML), inhibits canonical Notch transcription complex formation. SAHM1 can be used for the research of allergic airway inflammation in mice .

HY-162394

Vasopressin V2 receptor antagonist 2	Vasopressin Receptor	Metabolic Disease
Vasopressin V2 receptor antagonist 2 (Compound 33) is an antagonist of the arginine vasopressin V₂ receptor (V₂R) with a K_i value of 6.2 nM. Vasopressin V2 receptor antagonist 2 can effectively reduce cAMP levels, thereby inhibiting the growth of renal cysts[1].

HY-P5389

Connexin mimetic peptide 40GAP27	Gap Junction Protein	Others
Connexin mimetic peptide 40GAP27 is a biological active peptide. (This peptide corresponds to the GAP27 domain of the second extracellular loop of dominant vascular connexin (Cx40), designated as 40Gap 27. It was used to investigate mechanisms through which oxidant stress impairs communication via gap junctions. When administered, 40Gap27attenuates endothelium-dependent subintimal smooth muscle hyperpolarization.)

HY-P2473

Neurogranin (48-76), human	Calmodulin PKC CaMK PKA	Neurological Disease
Neurogranin (48-76), human is a dominant endogenous peptide in Alzheimer's disease (AD) brain tissue. Neurogranin (48-76) is a potential biomarker for synaptic function in AD .

HY-P3838

Protein Kinase C (gamma) Peptide	PKC	Others
Protein Kinase C γ Peptide is a peptide fragment of Protein Kinase Cγ. Protein Kinase Cγ is a protein causative for dominant ataxia, that can negatively regulate nuclear import of recessive-ataxia-related aprataxin .

HY-P5369

[Arg6]-β-Amyloid (1-42), england mutation	Peptides	Others
[Arg6]-β-Amyloid (1-42), england mutation is a biological active peptide. (Several mutations in the beta amyloid precursor gene cause autosomal dominant Alzheimer's Disease in a number of kindreds.Tthe English (H6R) mutation will disrupt H6 interactions.)

HY-P5368

[Arg6]-β-Amyloid (1-40), england mutation	Peptides	Others
[Arg6]-β-Amyloid (1-40), england mutation is a biological active peptide. (Several mutations in the beta amyloid precursor gene cause autosomal dominant Alzheimer's Disease in a number of kindreds. Among them, the English mutation, with His at position 6 replaced with Arg, was reported to accelerate the kinetics of oligomers formation which act as fibril seeds and are more toxic to cultured neuronal cells.)

HY-P5503

Pol (476-484), HIV-1 RT Epitope	HIV	Others
Pol (476-484), HIV-1 RT Epitope is a biological active peptide. (This is a reverse transcriptase (RT) epitope (Pol residues 476-484). Within HIV-1 RT the peptide appears to be the dominant HLA A*0201-restricted epitope. Was used to investigate possible mechanisms behind HIV-1 escape from CTL. IV9 is the actual epitope processed and presented in HIV-1-infected cell lines.)

HY-P5365

[Asn23] β-Amyloid (1-40), Iowa mutation	Peptides	Others
[Asn23] β-Amyloid (1-40), Iowa mutation is a biological active peptide. (Several mutations in the beta amyloid precursor gene cause autosomal dominant Alzheimer's Disease in a number of kindreds. The Iowa mutation, where Asp 23 is replaced with Asn, is associated with severe cerebral amyloid beta-protein angiopathy (CAA). The affected individuals share a missense mutation in APP at position 694. The mutated beta-amyloid peptide aggregates more rapidly and forms toxic fibrils.)

HY-P5331

[Asn23]-beta-Amyloid (1-42), iowa mutation	Peptides	Others
[Asn23]-beta-Amyloid (1-42), iowa mutation is a biological active peptide. (Several mutations in the beta amyloid precursor gene cause autosomal dominant Alzheimer's Disease in a number of kindreds. The Iowa mutation, where Asp 23 is replaced with Asn, is associated with severe cerebral amyloid beta-protein angiopathy (CAA). The affected individuals share a missense mutation in APP at position 694. The mutated beta-amyloid peptide aggregates more rapidly and forms toxic fibrils.)

Species:	Human (7)
Tag:	His (1) GST (1)
Source:	Sf9 insect cells (7)

Cat. No.	Compare	Product Name	Species	Source

HY-P72048

	BTK Protein, Human (sf9, His) Agammaglobulinaemia tyrosine kinase; AGMX 1; AGMX1; AT; ATK; B cell progenitor kinase; B-cell progenitor kinase; BPK; Bruton agammaglobulinemia tyrosine kinase; Bruton tyrosine kinase; Bruton Tyrosine Kinase; Btk; BTK_HUMAN; dominant-negative kinase-deficient Brutons tyrosine kinase; IMD 1; IMD1; MGC126261; MGC126262; OTTHUMP00000063593; PSCTK 1; PSCTK1; truncated Bruton agammaglobulinemia tyrosine kinase; Tyrosine protein kinase BTK; Tyrosine-protein kinase BTK; tyrosine-protein kinase BTK isoform lacking exon 14; XLA	Human	Sf9 insect cells
	The BTK protein is a key non-receptor tyrosine kinase that is essential for B lymphocyte development and signaling. After BCR activation, BTK initiates a cascade reaction, phosphorylates PLCG2 and activates downstream pathways, affecting calcium mobilization and PKC activation. BTK Protein, Human (sf9, His) is the recombinant human-derived BTK protein, expressed by sf9 insect cells , with N-10*His labeled tag.

HY-P704026

	BTK Protein, Human (sf9, GST, C481S) Agammaglobulinaemia tyrosine kinase; AGMX 1; AGMX1; AT; ATK; B cell progenitor kinase; B-cell progenitor kinase; BPK; Bruton agammaglobulinemia tyrosine kinase; Bruton tyrosine kinase; Bruton Tyrosine Kinase; Btk; BTK_HUMAN; dominant-negative kinase-deficient Brutons tyrosine kinase; IMD 1; IMD1; MGC126261; MGC126262; OTTHUMP00000063593; PSCTK 1; PSCTK1; truncated Bruton agammaglobulinemia tyrosine kinase; Tyrosine protein kinase BTK; Tyrosine-protein kinase BTK; tyrosine-protein kinase BTK isoform lacking exon 14; XLA	Human	Sf9 insect cells
	The BTK protein is a key non-receptor tyrosine kinase that is essential for B lymphocyte development and signaling. After BCR activation, BTK initiates a cascade reaction, phosphorylates PLCG2 and activates downstream pathways, affecting calcium mobilization and PKC activation. BTK Protein, Human (sf9, GST, C481S) is the recombinant human-derived BTK protein, expressed by Sf9 insect cells, with N-GST labeled tag.

HY-P704025

	BTK Protein, Human (sf9, GST) Agammaglobulinaemia tyrosine kinase; AGMX 1; AGMX1; AT; ATK; B cell progenitor kinase; B-cell progenitor kinase; BPK; Bruton agammaglobulinemia tyrosine kinase; Bruton tyrosine kinase; Bruton Tyrosine Kinase; Btk; BTK_HUMAN; dominant-negative kinase-deficient Brutons tyrosine kinase; IMD 1; IMD1; MGC126261; MGC126262; OTTHUMP00000063593; PSCTK 1; PSCTK1; truncated Bruton agammaglobulinemia tyrosine kinase; Tyrosine protein kinase BTK; Tyrosine-protein kinase BTK; tyrosine-protein kinase BTK isoform lacking exon 14; XLA	Human	Sf9 insect cells
	The BTK protein is a key non-receptor tyrosine kinase that is essential for B lymphocyte development and signaling. After BCR activation, BTK initiates a cascade reaction, phosphorylates PLCG2 and activates downstream pathways, affecting calcium mobilization and PKC activation. BTK Protein, Human (sf9, GST) is the recombinant human-derived BTK protein, expressed by Sf9 insect cells, with N-GST labeled tag.

HY-P704027

	BTK Protein, Human (sf9, GST, M437R) Agammaglobulinaemia tyrosine kinase; AGMX 1; AGMX1; AT; ATK; B cell progenitor kinase; B-cell progenitor kinase; BPK; Bruton agammaglobulinemia tyrosine kinase; Bruton tyrosine kinase; Bruton Tyrosine Kinase; Btk; BTK_HUMAN; dominant-negative kinase-deficient Brutons tyrosine kinase; IMD 1; IMD1; MGC126261; MGC126262; OTTHUMP00000063593; PSCTK 1; PSCTK1; truncated Bruton agammaglobulinemia tyrosine kinase; Tyrosine protein kinase BTK; Tyrosine-protein kinase BTK; tyrosine-protein kinase BTK isoform lacking exon 14; XLA	Human	Sf9 insect cells
	The BTK protein is a key non-receptor tyrosine kinase that is essential for B lymphocyte development and signaling. After BCR activation, BTK initiates a cascade reaction, phosphorylates PLCG2 and activates downstream pathways, affecting calcium mobilization and PKC activation. BTK Protein, Human (sf9, GST, M437R) is the recombinant human-derived BTK protein, expressed by Sf9 insect cells, with N-GST labeled tag.

HY-P704028

	BTK Protein, Human (sf9, GST, T316A) Agammaglobulinaemia tyrosine kinase; AGMX 1; AGMX1; AT; ATK; B cell progenitor kinase; B-cell progenitor kinase; BPK; Bruton agammaglobulinemia tyrosine kinase; Bruton tyrosine kinase; Bruton Tyrosine Kinase; Btk; BTK_HUMAN; dominant-negative kinase-deficient Brutons tyrosine kinase; IMD 1; IMD1; MGC126261; MGC126262; OTTHUMP00000063593; PSCTK 1; PSCTK1; truncated Bruton agammaglobulinemia tyrosine kinase; Tyrosine protein kinase BTK; Tyrosine-protein kinase BTK; tyrosine-protein kinase BTK isoform lacking exon 14; XLA	Human	Sf9 insect cells
	The BTK protein is a key non-receptor tyrosine kinase that is essential for B lymphocyte development and signaling. After BCR activation, BTK initiates a cascade reaction, phosphorylates PLCG2 and activates downstream pathways, affecting calcium mobilization and PKC activation. BTK Protein, Human (sf9, GST, T316A) is the recombinant human-derived BTK protein, expressed by Sf9 insect cells, with N-GST labeled tag.

HY-P704029

	BTK Protein, Human (sf9, GST, T474I) Agammaglobulinaemia tyrosine kinase; AGMX 1; AGMX1; AT; ATK; B cell progenitor kinase; B-cell progenitor kinase; BPK; Bruton agammaglobulinemia tyrosine kinase; Bruton tyrosine kinase; Bruton Tyrosine Kinase; Btk; BTK_HUMAN; dominant-negative kinase-deficient Brutons tyrosine kinase; IMD 1; IMD1; MGC126261; MGC126262; OTTHUMP00000063593; PSCTK 1; PSCTK1; truncated Bruton agammaglobulinemia tyrosine kinase; Tyrosine protein kinase BTK; Tyrosine-protein kinase BTK; tyrosine-protein kinase BTK isoform lacking exon 14; XLA	Human	Sf9 insect cells
	The BTK protein is a key non-receptor tyrosine kinase that is essential for B lymphocyte development and signaling. After BCR activation, BTK initiates a cascade reaction, phosphorylates PLCG2 and activates downstream pathways, affecting calcium mobilization and PKC activation. BTK Protein, Human (sf9, GST, T474I) is the recombinant human-derived BTK protein, expressed by Sf9 insect cells, with N-GST labeled tag.

HY-P704030

	BTK Protein, Human (sf9, GST, T474S) Agammaglobulinaemia tyrosine kinase; AGMX 1; AGMX1; AT; ATK; B cell progenitor kinase; B-cell progenitor kinase; BPK; Bruton agammaglobulinemia tyrosine kinase; Bruton tyrosine kinase; Bruton Tyrosine Kinase; Btk; BTK_HUMAN; dominant-negative kinase-deficient Brutons tyrosine kinase; IMD 1; IMD1; MGC126261; MGC126262; OTTHUMP00000063593; PSCTK 1; PSCTK1; truncated Bruton agammaglobulinemia tyrosine kinase; Tyrosine protein kinase BTK; Tyrosine-protein kinase BTK; tyrosine-protein kinase BTK isoform lacking exon 14; XLA	Human	Sf9 insect cells
	The BTK protein is a key non-receptor tyrosine kinase that is essential for B lymphocyte development and signaling. After BCR activation, BTK initiates a cascade reaction, phosphorylates PLCG2 and activates downstream pathways, affecting calcium mobilization and PKC activation. BTK Protein, Human (sf9, GST, T474S) is the recombinant human-derived BTK protein, expressed by Sf9 insect cells, with N-GST labeled tag.

Compare Products


Products	In-stock - + Add to Cart
Cat. No.
Species
Source
Tag
Accession
Gene ID
Molecular Weight
Purity
Endotoxin Level
Biological Activity
Appearance
Formulation
Storage & Stability
Shipping
Free Sample	Yes No
Size	* This product has been "discontinued". Optimized version of product available: / In-stock - + Add to Cart Get quote

Cat. No.	Compare	Product Name	Application	Reactivity

HY-P81101

	Collagen III Antibody COL 3A1; COL3A1; Collagen alpha 1(III) chain; Collagen III alpha 1 chain precursor; Collagen III alpha 1 polypeptide; Collagen type III alpha 1 (Ehlers Danlos syndrome type IV autosomal dominant); Collagen type III alpha 1; Collagen type III alpha; EDS4A; Ehlers Danlos syndrome type IV, autosomal dominant; Fetal collagen; Type III collagen; CO3A1_HUMAN; Collagen alpha-1(III) chain; Type III collagen; type III preprocollagen alpha 1 chain.	WB, ELISA, IHC-P, IHC-F, ICC/IF	Human, Dog, Rabbit
	Collagen III Antibody is an unconjugated, approximately 117 kDa, rabbit-derived, anti-Collagen III polyclonal antibody. Collagen III Antibody can be used for: WB, ELISA, IHC-P, IHC-F, IF expriments in human, dog, rabbit, and predicted: mouse, rat, chicken, cow background without labeling.

HY-P83524

	Rhodopsin Antibody (YA3269) CSNBAD1; OPN2; opsd; Opsin 2 rod pigment; Opsin2; Retinitis pigmentosa 4 autosomal dominant; RHO; Rhodopsin; RP4	WB, IHC-P	Human, Rat
	Rhodopsin Antibody (YA3269) is a rabbit-derived non-conjugated IgG antibody (Clone NO.: YA3269), targeting Rhodopsin, with a predicted molecular weight of 39 kDa (observed band size: 39 kDa). Rhodopsin Antibody (YA3269) can be used for WB, IHC-P experiment in human, rat background.

HY-P86969

	MYH2 Antibody (YA6662) adult 2 antibody; Fast 2a myosin heavy chain antibody; IBM3 antibody; Inclusion body myopathy 3, autosomal dominant antibody; MYH2 antibody; MYH2_HUMAN antibody; MYH2A antibody; MYHas8 antibody; MyHC IIa antibody; MyHC-2a antibody; adult 2 antibody; Fast 2a myosin heavy chain antibody; IBM3 antibody; Inclusion body myopathy 3, autosomal dominant antibody; MYH2 antibody; MYH2_HUMAN antibody; MYH2A antibody; MYHas8 antibody; MyHC IIa antibody; MyHC-2a antibody; MyHC-IIa antibody; MYHSA2 antibody; Myosin heavy chain 2 antibody; Myosin heavy chain 2a antibody; Myosin heavy chain antibody; Myosin heavy chain IIa antibody; Myosin heavy chain skeletal muscle adult 2 antibody; Myosin heavy polypeptide 2 skeletal muscle adult antibody; Myosin-2 antibody; MYPOP antibody; skeletal muscle antibody; Type IIA myosin heavy chain antibody	WB, IHC-P	Human, Mouse, Rat

HY-P87082

	SOX10 Antibody (YA6775) DOM antibody; DOM antibody; dominant megacolon mouse human homolog of antibody; MGC15649 antibody; PCWH antibody; SOX 10 antibody; SOX10 antibody; SOX10_HUMAN antibody; SRY (sex determining region Y) box 10 antibody; SRY (sex determining region Y) box 10 antibody; DOM antibody; DOM antibody; dominant megacolon mouse human homolog of antibody; MGC15649 antibody; PCWH antibody; SOX 10 antibody; SOX10 antibody; SOX10_HUMAN antibody; SRY (sex determining region Y) box 10 antibody; SRY (sex determining region Y) box 10 antibody; SRY box 10 antibody; SRY box containing gene 10 antibody; SRY related HMG box gene 10 antibody; SRY related HMG box gene 10 antibody; Transcription factor SOX 10 antibody; Transcription factor SOX-10 antibody; WS2E antibody; WS4 antibody; WS4C antibody	IHC-F, IHC-P, IF-Tissue	Mouse, Rat

HY-P82974

	Cardiac Troponin T Antibody (YA2719) TNNT2; Cardiac muscle troponin T; Troponin T; cardiac muscle; troponin T type 2 (cardiac); Cardiac muscle troponin T antibody Cardiomyopathy dilated 1D (autosomal dominant) antibody; Cardiomyopathy hypertrophic 2 antibody; CMD1D antibody; CMH2 antibody; CMPD2 antibody; cTnT antibody; LVNC6 antibody; MGC3889 antibody; OTTHUMP00000033864 antibody; RCM3 antibody; TNNT 2 antibody; TNNT2 antibody; TNNT2_HUMAN antibody; TnTc antibody; Troponin T cardiac muscle antibody; Troponin T2 cardiac antibody	WB, IHC-P	Human, Mouse, Rat
	Cardiac Troponin T Antibody (YA2719) is a rabbit-derived non-conjugated IgG antibody (Clone NO.: YA2719), targeting Cardiac Troponin T, with a predicted molecular weight of 36 kDa (observed band size: 40 kDa). Cardiac Troponin T Antibody (YA2719) can be used for WB, IHC-P experiment in human, mouse, rat background.

HY-P85834

	Mucin 1 Antibody (YA5526) ADMCKD; ADMCKD1; Breast carcinoma associated antigen DF3; Breast carcinoma-associated antigen DF3; CA 15-3; CA15 3; CA15 3 antigen; CA15-3; CA15.3; Cancer antigen 15-3; Carcinoma associated mucin; Carcinoma-associated mucin; CD 227; CD227; DF3 antigen; EMA; Episialin; Epithelial Membrane Antigen; H23 antigen; H23AG; KL 6; KL-6; KL6; Krebs von den Lungen-6; MAM 6; MAM6; MCD; MCKD; MCKD1; Medullary cystic kidney disease 1; autosomal dominant; Medullary cystic kidney disease, autosomal dominant; MUC 1; MUC-1; MUC-1/SEC; MUC-1/X; MUC1; MUC1-alpha; MUC1-beta; MUC1-CT; MUC1-NT; MUC1/ZD; MUC1_HUMAN; Mucin 1; Mucin 1 cell surface associated; Mucin 1 transmembrane; Mucin 1, cell surface associated; Mucin-1 subunit beta; Peanut reactive urinary mucin; Peanut-reactive urinary mucin; PEM; PEMT; Polymorphic epithelial mucin; PUM; Tumor associated epithelial membrane antigen; Tumor associated epithelial mucin; Tumor associated mucin; Tumor-associated epithelial membrane antigen; Tumor-associated mucin	IHC-P, WB, ICC/IF, ELISA	Human
	Mucin 1 Antibody (YA5526) is a mouse-derived and non-conjugated IgG1 monoclonal antibody, targeting to Mucin 1. It can be applicated for IHC-P, WB, ICC/IF, ELISA assays, in the background of human.

HY-P86998

	OPA1 Antibody (YA6691) Dynamin like 120 kDa protein antibody; Dynamin like 120 kDa protein, mitochondrial antibody; Dynamin-like 120 kDa protein, form S1 antibody; FLJ12460 antibody; Juvenile kjer type optic atrophy antibody; KIAA0567 antibody; KJER type antibody; Large GTP binding protein antibody; largeG antibody; MGM1 antibody; Dynamin like 120 kDa protein antibody; Dynamin like 120 kDa protein, mitochondrial antibody; Dynamin-like 120 kDa protein, form S1 antibody; FLJ12460 antibody; Juvenile kjer type optic atrophy antibody; KIAA0567 antibody; KJER type antibody; Large GTP binding protein antibody; largeG antibody; MGM1 antibody; Mitochondrial dynamin like 120 kDa protein antibody; Mitochondrial dynamin like GTPase antibody; NPG antibody; NTG antibody; OAK antibody; OPA 1 antibody; opa1 antibody; OPA1 gene antibody; OPA1_HUMAN antibody; Optic atrophy 1 (autosomal dominant) antibody; OPTIC ATROPHY 1 antibody; Optic atrophy 1 gene protein antibody; Optic atrophy 1 homolog (human) antibody; Optic atrophy protein 1 antibody; Optic atrophy protein 1 homolog antibody	WB, IHC-P, ICC/IF, FC, IP	Human, Mouse, Rat